恆瑞醫藥(600276.SH): 子公司他氟前列素滴眼液擬納入優先審評
格隆匯5月28日丨恆瑞醫藥(600276.SH)宣佈,公司子公司成都盛迪醫藥有限公司的他氟前列素滴眼液近日被國家藥品監督管理局藥品審評中心納入擬優先審評品種公示名單,公示期7日。
他氟前列素為前列腺素類似物,是一種選擇性FP前列腺素受體激動劑,可通過增加葡萄膜鞏膜途徑房水流出量來降低眼內壓。用於降低開角型青光眼和高眼壓症患者升高的眼壓。
他氟前列素滴眼液最早在美國獲批上市銷售,現已在中國獲批上市。目前同類產品有貝美前列素滴眼液(商品名LUMIGAN)、曲伏前列素(商品名TRAVATANZ)和拉坦前列素(商品名XALATAN)。經查詢,2019年他氟前列素滴眼液全球銷售額約為1.85億美元。
2020年1月10日,國家藥品監督管理局藥品審評中心承辦成都盛迪醫藥有限公司此次遞交的藥品註冊申請。截至目前,公司在該研發項目上已投入研發費用約為1447萬元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.